Director/PDMR Shareholding
April 24 2007 - 12:03PM
UK Regulatory
RNS Number:4376V
Sagentia Group AG
24 April 2007
SAGENTIA GROUP AG
('the Company')
On the 19th April, 2007 Martin Forster, a non executive director and
the Company Secretary of Sagentia Group AG, informed the Company
that on the 18th April 2007 he has purchased additional 200,000 shares of CHF
0.10 each in Sagentia Group AG at 7.25 pence per share. His total holding of CHF
0.10 shares now stands at 1,299,400 shares.
Enquiries:
The Generics Group AG
Martin Frost (44) 1223 875200
www.genericsgroup.com
Hansard Group
Andrew Tan (44) 207 2451100
www.hansardgroup.co.uk
Notes to editors:
Sagentia Group AG
Sagentia Group is a leading international technology consulting and venturing
organisation, with a reputation for successfully commercialising emerging
science and technology. The Group comprises two principal operating companies,
Sagentia and Chord Capital.
Sagentia is one of the world's pre-eminent technology management and product
development companies. For 20 years the business has shown an unwavering
commitment to innovation that has led to the launch of breakthrough products.
Sagentia's facilities include state-of-the-art laboratories and are located in
Europe in Cambridge, Frankfurt, and Stockholm; in Boston and Baltimore in the
USA and in Hong Kong.
The Group's venture management activities are managed through its FSA-regulated
fund manager Chord Capital Limited. Through Chord Capital, venture and investee
companies gain access to business building and corporate finance skills. Recent
ventures and investments include CMR Fuel Cells plc and Nanoscience plc, listed
on AIM, Sphere Medical Ltd and Atraverda Ltd.
Sagentia Group is quoted on the LSE (SGA.L)
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSSESFILSWSEDL
Sagentia Grp (LSE:SGA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Sagentia Grp (LSE:SGA)
Historical Stock Chart
From Jan 2024 to Jan 2025
